Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
174
-
Total 13F shares, excl. options
-
27.3M
-
Shares change
-
+2.12M
-
Total reported value, excl. options
-
$1.28B
-
Value change
-
+$105M
-
Put/Call ratio
-
0.83
-
Number of buys
-
80
-
Number of sells
-
-61
-
Price
-
$47.10
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2019
221 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q2 2019.
CRISPR Therapeutics AG - Common Stock (CRSP) has 174 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.3M shares
of 86M outstanding shares and own 31.73% of the company stock.
Largest 10 shareholders include Versant Venture Management, LLC (4.25M shares), ARK Investment Management LLC (2.72M shares), NEA Management Company, LLC (2.09M shares), Nikko Asset Management Americas, Inc. (1.87M shares), EcoR1 Capital, LLC (1.61M shares), WELLINGTON MANAGEMENT GROUP LLP (1.28M shares), Abingworth LLP (1.17M shares), WADDELL & REED FINANCIAL INC (1M shares), FEDERATED INVESTORS INC /PA/ (832K shares), and Bellevue Group AG (810K shares).
This table shows the top 174 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.